Skip to main content

Market Overview

Benzinga's Top Upgrades

Share:
Benzinga's Top Upgrades

Analysts at Citigroup upgraded Biogen Idec (NASDAQ: BIIB) from “neutral” to “buy.” The target price for Biogen Idec is set to $236. Biogen Idec's shares closed at $215.20 on Friday.

Analysts at Piper Jaffray upgraded Regeneron Pharmaceuticals (NASDAQ: REGN) from “neutral” to “overweight.” The target price for Regeneron Pharmaceuticals is set to $274. Regeneron's shares closed at $224.88 on Friday.

Analysts at Morgan Stanley upgraded Whitewave Foods (NYSE: WWAV) from “equal-weight” to “overweight.” The target price for Whitewave Foods is set to $19. Whitewave's shares closed at $16.25 on Friday.

BMO Capital upgraded First Majestic Silver (NYSE: AG) from “market perform” to “outperform.” The target price for First Majestic Silver has been lowered from $18 to $13. First Majestic Silver's shares closed at $10.59 on Friday.

Latest Ratings for BIIB

DateFirmActionFromTo
Apr 2021Morgan StanleyMaintainsOverweight
Apr 2021WedbushMaintainsNeutral
Feb 2021Cantor FitzgeraldMaintainsNeutral

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

 

Related Articles (BIIB + REGN)

View Comments and Join the Discussion!

Posted-In: top upgradesUpgrades Analyst Ratings

Latest Ratings

StockFirmActionPT
ICADGuggenheimInitiates Coverage On24.0
SMBKRaymond JamesUpgrades27.0
WNSNeedhamMaintains88.0
EFXNeedhamMaintains260.0
GOOGLJefferiesMaintains2,700.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com